ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the LEERINK Partners Rare Disease Roundtable Series in New York City on Wednesday, September 27, 2017, at 9:30 a.m. Eastern Time. A live webcast of the event will be available through the Events and Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com, and a replay of the presentation will be available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for Meniere's disease and other vestibular disorders (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
Media contact: David Schull, Russo Partners, 1-858-717-2310,
[email protected]


Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



